Cerenome, Inc.
CNSYHealthcare|Medical - Pharmaceuticals|US
$0.64
-0.03 (-4.06%)
DCF Value
$2.01
Tangible Book / Share
$0.71
Cash / Share
$1.27
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT01906385 Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Glioma | P1P2 | Recruiting | 55 | Open-label | Rhenium Liposome Treatment |
| NCT07098806 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | Leptomeningeal Metastasis | P1P2 | Recruiting | 24 | Open-label | 186RNL |
| NCT07061626 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | Ependymoma, High Grade Gliomas | P1 | Recruiting | 56 | Open-label | Rhenium-186 Nanoliposome |
| NCT05460507 Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | Glioma | P1 | Recruiting | 40 | Open-label | Retreatment Rhenium Liposome |
| NCT05034497 Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | Leptomeningeal Metastasis | P1 | Completed | 37 | Open-label | 186RNL |